267 related articles for article (PubMed ID: 25808626)
1. Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naïve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus.
Setkina S; Dotsenko M; Bondar S; Charnysh I; Kuchko A; Kaznacheeva A; Kozorez E; Dodaleva A; Rossa N
Drug Saf; 2015 Apr; 38(4):365-72. PubMed ID: 25808626
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
[TBL] [Abstract][Full Text] [Related]
3. A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.
Dube NM; Summers R; Tint KS; Mayayise G
Pan Afr Med J; 2012; 11():39. PubMed ID: 22593775
[TBL] [Abstract][Full Text] [Related]
4. Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients.
Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Yankey BA; Dodoo AN
Drug Saf; 2016 Nov; 39(11):1139-1149. PubMed ID: 27638659
[TBL] [Abstract][Full Text] [Related]
5. A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.
Masuka JT; Chipangura P; Nyambayo PP; Stergachis A; Khoza S
Clin Drug Investig; 2018 Jan; 38(1):9-17. PubMed ID: 28965312
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
Sreenivasan S; Dasegowda V
J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454
[TBL] [Abstract][Full Text] [Related]
7. Influence of adverse drug reactions on treatment success: prospective cohort analysis of HIV-infected individuals initiating first-line antiretroviral therapy in India.
Shet A; Antony J; Arumugam K; Kumar Dodderi S; Rodrigues R; DeCosta A
PLoS One; 2014; 9(3):e91028. PubMed ID: 24614165
[TBL] [Abstract][Full Text] [Related]
8. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia.
Mann M; Mengistu A; Gaeseb J; Sagwa E; Mazibuko G; Baeten JM; Babigumira JB; Garrison LP; Stergachis A
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1052-60. PubMed ID: 27134056
[TBL] [Abstract][Full Text] [Related]
9. Adverse drug reactions of Highly Active Antiretroviral Therapy (HAART) in HIV infected patients at the General Hospital, Douala, Cameroon: a cross sectional study.
Namme Luma H; Doualla MS; Choukem SP; Temfack E; Ashuntantang G; Achu Joko H; Koulla-Shiro S
Pan Afr Med J; 2012; 12():87. PubMed ID: 23077708
[TBL] [Abstract][Full Text] [Related]
10. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India.
Mukherjee S; Era N; Saha B; Tripathi SK
Indian J Pharmacol; 2017; 49(3):223-228. PubMed ID: 29033481
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Adverse Drug Reactions to Highly Active Antiretroviral Therapy (HAART) among HIV Positive Patients in Imam Khomeini Hospital of Tehran, Iran.
Koochak HE; Babaii A; Pourdast A; Golrokhy R; Rasoolinejad M; Khodaei S; Moghadam SRJ; Taheri RR; Seyed Alinaghi SA
Infect Disord Drug Targets; 2017; 17(2):116-119. PubMed ID: 28164754
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
[TBL] [Abstract][Full Text] [Related]
15. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children.
Kenny J; Musiime V; Judd A; Gibb D
Curr Opin HIV AIDS; 2012 Jul; 7(4):305-16. PubMed ID: 22678488
[TBL] [Abstract][Full Text] [Related]
17. HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Anwikar SR; Bandekar MS; Smrati B; Pazare AP; Tatke PA; Kshirsagar NA
Int J Risk Saf Med; 2011; 23(3):163-9. PubMed ID: 22020396
[TBL] [Abstract][Full Text] [Related]
18. Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan of Kwa-Zulu Natal, South Africa: a cross-sectional and retrospective comparative study.
Zondi SL; Naidoo P
Pan Afr Med J; 2022; 42():218. PubMed ID: 36845236
[TBL] [Abstract][Full Text] [Related]
19. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
20. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
